Efficacy And Safety Of Bradykinin B2 Receptor Inhibition With Oral PHVS416 In Treating Hereditary Angioedema Attacks: Results Of RAPIDe-1 Phase 2 Trial

Marcus Maurer,John Anderson, Emel Aygoeren-Puersuen,Laurence Bouillet,Maria Luisa Baeza,Hugo Chapdelaine,Danny Cohn,Aureline Du-Thanh,Olivier Fain,Henriette Farkas,Jens Greve,Mar Guilarte,David Hagin,Roman Hakl,Joshua Jacobs, Aharon Kessell,Sorena Kiani-Alikhan,Pavlina Kralickova,Huamin Li, Ramon Lleonart Bellfill,Markus Magerl, Michael Manning,Avner Reshef,Bruce Ritchie,Giuseppe Spadaro,Maria Staevska,Petra Staubach,Marcin Stobiecki,Gordon Sussman,Michael Tarzi,Anna Valerieva,William Yang, Marie-Helene Jouvin, Rafael Crabbe, Simone van Leeuwen, Huaihou Chen, Li Zhu, Jochen Knolle, Anne Lesage,Peng Lu,Marc Riedl

Journal of Allergy and Clinical Immunology（2023）

引用 2|浏览36

暂无评分

摘要

In hereditary angioedema (HAE), swelling attacks are caused by excessive bradykinin activating the bradykinin B2 receptors. PHA121 is a potent, selective antagonist of bradykinin B2 receptors being investigated for on-demand and prophylactic treatment of HAE attacks.

查看译文

关键词

hereditary angioedema attacks,bradykinin b2 receptor inhibition,oral phvs416

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要